Study terms
Terminal vs effective half-life
A concentration-time curve can behave like a landscape with more than one slope. It may fall quickly at first, then settle into a slower late decline. That is why two half-life values can both be legitimate while answering different questions.
The distinction matters because a reader may see a long terminal half-life and assume the whole experience lasted that long, or see a shorter effective half-life and miss a slow tail. The right interpretation depends on the sampling window, model, route, formulation, and purpose of the estimate.
Terminal half-life
Terminal half-life is estimated from the final, slowest portion of the concentration-time curve. It can be useful when persistence matters, especially when a substance distributes into tissues or has a late phase that would be missed by short sampling.
The caution is that terminal does not always mean practically dominant. A terminal slope may describe a period after the main clinical or subjective effects have faded. It may also be hard to estimate well if the study did not collect enough late samples.
Effective half-life
Effective half-life is a more practical summary used around accumulation and repeated exposure. FDA labeling guidance notes that elimination half-life information may include effective half-life based on time to steady state. In other words, the number may be chosen because it helps explain the pattern that matters for use over time.
Effective half-life can be more useful for repeated exposure questions, but it is still not universal. It can shift with formulation, route, concentration range, organ function, interactions, and the model used by the study.
Why the same source may mention both
- A drug can distribute quickly from blood into tissues, then decline more slowly later.
- A late terminal phase can affect persistence without explaining the main effect window.
- Repeated exposure can make an effective value more useful than a terminal slope for accumulation.
- Short or sparse sampling can make terminal estimates unstable.
How HalfLifeDB handles one-number pages
HalfLifeDB usually needs one representative value to power a clear chart. When a source reports multiple values, the page notes should explain which value is being used and why. A single curve is easier to read than a full pharmacokinetic model, but the simplification should stay visible.
If a profile page includes a long half-life, treat the chart as a persistence visualization first. If the question is duration, impairment, repeated exposure, or clinical management, the source context matters more than the visual curve.